文献速递流行病学与生物统计医学教育与科研方法

随机对照试验的前瞻性注册:现状、原因及改进路径

Prospective registration of trials: where we are, why, and how we could get better.
PubMed 文献 · J Clin Epidemiol · 2024-10-30

该研究检索2009至2022年发表的1093项风湿病学随机对照试验,发现453项(41.4%)未在前瞻性注册,其中130项(11.9%)未注册、323项(29.5%)为回顾性注册;前瞻性注册比例每年增加3%(P < .001),从2009年的13.3%(2/15)升至2022年的73.2%(112/153)。作者认为依从性仍不理想,建议针对期刊编辑、卫生专业人员和研究者采取策略。

要点

  • 风湿病学随机对照试验中41.4%未前瞻性注册,11.9%未注册、29.5%回顾性注册。
  • 前瞻性注册比例每年增加3%(P < .001),2022年达73.2%。
  • 未前瞻性注册者报告主要原因为缺乏知识或组织问题,建议将伦理批准与试验注册挂钩。

核心结论

  • 尽管有显著改善,风湿病学随机对照试验的前瞻性注册依从性仍不令人满意;针对期刊编辑、卫生专业人员和研究者的定向策略可能有助于改善试验注册。

研究设计与样本

  • 研究检索2009年至2022年发表的风湿病学随机对照试验,采用多变量逻辑回归分析与前瞻性注册相关的因素,并向未前瞻性注册的试验研究者发放问卷调查不依从原因及可能的解决方案。

主要发现

  • 共纳入1093项随机对照试验,453项(41.4%)未前瞻性注册,其中130项(11.9%)未注册、323项(29.5%)为回顾性注册。
  • 前瞻性注册每年增加3%(P < .001),2009年注册比例为13.3%(2/15),2022年为73.2%(112/153)。
  • 在支持国际医学期刊编辑委员会(International Committee of Medical Journal Editors)推荐的期刊中,2022年发表的试验有16%未前瞻性注册。
  • 前瞻性注册与较大样本量、多国招募及发表于较高影响因子期刊相关。
  • 研究者报告缺乏知识或组织问题为回顾性注册的关键原因,并建议将伦理批准与试验注册挂钩以确保前瞻性注册。

关键数值与推荐

  • 前瞻性注册定义为在首例受试者入组前注册随机对照试验。
  • 未前瞻性注册包括未注册(11.9%)和回顾性注册(29.5%)。

临床怎么用

  • 作者认为针对期刊编辑、卫生专业人员和研究者的定向策略可能有助于改善试验注册。
  • 研究者建议将伦理批准与试验注册挂钩以确保前瞻性注册。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Transparent trial conduct requires prospective registration of a randomized controlled clinical trial (RCT) before the enrollment of the first participant. We aimed to (1) estimate the proportion of RCTs that are prospectively registered and analyze the time trends and factors linked to registration timing and (2) assess the reasons for nonadherence to prospective registration and explore ways to improve compliance. We studied trials published in rheumatology as a case study. STUDY DESIGN AND SETTING: We searched for RCTs in rheumatology published between 2009 and 2022. We conducted a multivariable logistic regression to identify factors associated with prospective trial registration. We sent a survey to investigators of trials not prospectively registered, asking about reasons for nonadherence and potential solutions. RESULTS: We identified 1093 RCTs; 453 (41.4%) were not prospectively registered. Of these, 130 (11.9%) were not registered and 323 (29.5%) were retrospectively registered. Prospective registration increased by 3% annually (P < .001), with 13.3% (2 of 15) trials registered in 2009 to 73.2% (112 of 153) in 2022. In journals supporting the International Committee of Medical Journals Editors recommendations, 16% of trials published in 2022 were not prospectively registered. Prospective registration was associated with a larger sample size, multinational recruitment, and publication in higher impact journals. Investigators reported lack of knowledge or organizational problems as key reasons for retrospective registration. They suggested linking ethical approval to trial registration to ensure prospective registration. CONCLUSION: Despite significant improvement, adherence to prospective registration remains unsatisfactory in rheumatology. Targeted strategies for journal editors, health-care professionals, and researchers may help improve trial registration. PLAIN LANGUAGE SUMMARY: Randomized controlled clinical trials are a research type where people are randomly assigned to different treatments to see which works best. These treatments can include drugs, surgery, medical devices, or changes in behavior. The results obtained in RCTs are essential for the advance of medicine and for making medical decisions. Randomized controlled clinical trials need to be conducted in a transparent way to provide trustworthy information and avoid misleading findings. A key aspect of transparency is registering the study details and plan in a public repository before the trial starts. This not only requires researchers to plan their study in advance but also enables the scientific community to track any change in how the study is conducted. Although registration of RCTs is recommended, it is not compulsory. Questions remain about researchers' compliance with prospective registration, and the factors that may affect it. In the present study, we systematically studied the registration practices of rheumatology RCTs published between 2009 and 2022. We reviewed how the trials were registered and used a statistical method (multivariable logistic regression) to determine what factors were linked to whether a trial was registered before it started. We also sent a questionnaire to researchers who either did not register or retrospectively registered their study, asking for their suggestions on how to improve adherence to proper registration practices. We found 1093 trials, of which 453 (41.4%) were not registered before they started. Among these, 130 (11.9%) were never registered and 323 (29.5%) were retrospectively registered. Trials with a larger number of participants, those involving recruiting centers from multiple countries, and those published in more prestigious journals were more likely to be registered in advance and adhere to transparency recommendations. Researchers who did not register their trial before it started reported that lack of awareness and organizational issues as the main reasons for not following these recommendations. They suggested that connecting ethical approval to trial registration could be a solution for ensuring adequate registration. We found that even though trial registration has improved in recent years, a considerable number of rheumatology trials are still not registered before they start. Based on our findings, we think that focusing on strategies for journal editors, health-care professionals, and researchers could help increase the number of properly registered trials.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Mongin D, Buitrago-Garcia D, Capderou S, et al. Prospective registration of trials: where we are, why, and how we could get better. J Clin Epidemiol. 2024. PMID: 39481460. doi:10.1016/j.jclinepi.2024.111586

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。